Noelia Villarrubia
Overview
Explore the profile of Noelia Villarrubia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dominguez-Mozo M, Lopez-Mecandez D, Villar L, Costa-Frossard L, Villarrubia N, Aladro Y, et al.
Ann Clin Transl Neurol
. 2025 Mar;
PMID: 40033709
Objective: An alteration in the composition of the intestinal microbiota has been observed in patients with multiple sclerosis (pwMS) with respect to healthy controls (HC). Microorganism-derived metabolites such as short-chain...
2.
Comabella M, Pappolla A, Monreal E, Fissolo N, Sao-Aviles A, Arrambide G, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200370.
PMID: 39879564
Background And Objectives: Invasive procedures may delay the diagnostic process in multiple sclerosis (MS). We investigated the added value of serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP),...
3.
Rodriguez-Jorge F, Fernandez-Velasco J, Villarrubia N, Gracia-Gil J, Fernandez E, Meca-Lallana V, et al.
Front Immunol
. 2025 Jan;
15:1535051.
PMID: 39749346
[This corrects the article DOI: 10.3389/fimmu.2024.1480676.].
4.
Sainz-Amo R, Rodero-Romero A, Monreal E, Chico-Garcia J, Rodriguez-Jorge F, Fernandez-Velasco J, et al.
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684862
Natalizumab is a highly effective therapy for multiple sclerosis (MS). The aim of this study was to evaluate serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP)...
5.
Rodriguez-Jorge F, Fernandez-Velasco J, Villarrubia N, Gracia-Gil J, Fernandez E, Meca-Lallana V, et al.
Front Immunol
. 2024 Nov;
15:1480676.
PMID: 39606235
Objective: To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing-remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association...
6.
Navarrete-Perez A, Gomez-Melero S, Escribano B, Galvao-Carmona A, Conde-Gavilan C, Pena-Toledo M, et al.
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337497
There is substantial evidence supporting the neuroprotective effects of the MIND diet in neurodegenerative diseases like Parkinson's and Alzheimer's. Our aim was to evaluate the impact of a nutritional intervention...
7.
Sainz De La Maza S, Rodero-Romero A, Monreal E, Chico-Garcia J, Villarrubia N, Rodriguez-Jorge F, et al.
Front Immunol
. 2024 Sep;
15:1439393.
PMID: 39238642
Objective: To evaluate the safety of COVID-19 vaccines in patients with multiple sclerosis (MS) by assessing their impact on serum neurofilament light chain (sNfL) levels as a marker of neuroaxonal...
8.
Sainz-Amo R, Rodero Romero A, Monreal E, Chico Garcia J, Fernandez Velasco J, Villarrubia N, et al.
Front Immunol
. 2024 Sep;
15:1454474.
PMID: 39224593
Introduction: Alemtuzumab is a highly effective pulsed immune reconstitution therapy for multiple sclerosis (MS). Aim: To evaluate serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) in...
9.
Tortosa-Carreres J, Cubas-Nunez L, Piqueras M, Castillo-Villalba J, Quintanilla-Bordas C, Quiroga-Varela A, et al.
J Neuroimmunol
. 2024 Aug;
394:578428.
PMID: 39121816
Immunohistochemical studies have identified complement component C1q in MS lesions. We aimed to compare serum (sC1q) and CSF (csfC1q) levels in a large cohort of MS patients (pwMS) (n = ...
10.
Monreal E, Fernandez-Velasco J, Alvarez-Lafuente R, Sainz De La Maza S, Garcia-Sanchez M, Llufriu S, et al.
Brain
. 2024 Aug;
147(12):4084-4093.
PMID: 39101570
The potential for combining serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels to predict worsening disability in multiple sclerosis remains underexplored. We aimed to investigate whether...